Analysts Offer Insights on Healthcare Companies: Bellerophon (NASDAQ: BLPH) and Pluristem (NASDAQ: PSTI)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bellerophon (NASDAQ: BLPH) and Pluristem (NASDAQ: PSTI) with bullish sentiments.

Bellerophon (NASDAQ: BLPH)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Bellerophon (NASDAQ: BLPH), with a price target of $5. The company’s shares closed yesterday at $1.18.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.3% and a 50.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Bellerophon has an analyst consensus of Moderate Buy, with a price target consensus of $5.

Pluristem (NASDAQ: PSTI)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Pluristem (NASDAQ: PSTI) today and set a price target of $3.50. The company’s shares closed yesterday at $1.19.

According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -8.3% and a 32.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as X T L Biopharmaceuticals Ltd (ADR), Strata Skin Sciences Inc, and Spectrum Pharmaceuticals.

Currently, the analyst consensus on Pluristem is Moderate Buy and the average price target is $2.75, representing a 132.1% upside.

In a report released yesterday, Maxim Group also assigned a Buy rating to the stock with a $2 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.